Advertisement

Dysregulation of Circadian System in Parkinson’s Disease

  • Aleksandar VidenovicEmail author
Chapter
  • 1k Downloads

Abstract

Circadian rhythms are physiological and behavioral cycles with a periodicity of approximately 24 h, generated by the endogenous biological clock, the suprachiasmatic nucleus (SCN). These rhythms influence most physiological processes, including the sleep–wake cycle. The exact pathophysiology of sleep–wake disturbances in Parkinson’s disease (PD) remains largely unknown, but the etiology is likely to be multifactorial, including influence of motor PD symptoms on sleep, adverse effects of antiparkinsonian medications, and neurodegeneration of central sleep regulatory areas. The circadian system and its main central pacemaker, the SCN, have a major influence on sleep–wake homeostasis. A growing body of evidence points to significant alterations of the circadian system in PD. Despite this, little is known about the role of the circadian system in the regulation of sleep–wake cycles in PD. In this chapter, we discuss the role of the circadian system in the regulation of the sleep–wake cycle and outline implications of circadian timekeeping in PD.

Keywords

Clock Gene Circadian System Wake Cycle Circadian Disruption Melatonin Rhythm 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Golombek DA, Rosenstein RE. Physiology of circadian entrainment. Physiol Rev. 2010;90(3):1063–102.CrossRefPubMedGoogle Scholar
  2. 2.
    Dardente H, Cermakian N. Molecular circadian rhythms in central and peripheral clocks in mammals. Chronobiol Int. 2007;24(2):195–213.CrossRefPubMedGoogle Scholar
  3. 3.
    Cermakian N, Boivin DB. The regulation of central and peripheral circadian clocks in humans. Obes Rev. 2009;10 Suppl 2:25–36.CrossRefPubMedGoogle Scholar
  4. 4.
    Takahashi JS, Hong HK, Ko CH, McDearmon EL. The genetics of mammalian circadian order and disorder: implications for physiology and disease. Nat Rev. 2008;9(10):764–75.CrossRefGoogle Scholar
  5. 5.
    Daan S, Pittendrigh CS. A functuional analysis of circadian pacemakers in nocturnal rodents. II. The variability of phase response curve. J Comp Physiol. 1976;106:253.CrossRefGoogle Scholar
  6. 6.
    Lewy AJ. Melatonin as a marker and phase-resetter of circadian rhythms in humans. Adv Exp Med Biol. 1999;460:425–34.CrossRefPubMedGoogle Scholar
  7. 7.
    Lewy AJ, Cutler NL, Sack RL. The endogenous melatonin profile as a marker for circadian phase position. J Biol Rhythms. 1999;14(3):227–36.CrossRefPubMedGoogle Scholar
  8. 8.
    Selmaoui B, Touitou Y. Reproducibility of the circadian rhythms of serum cortisol and melatonin in healthy subjects: a study of three different 24-h cycles over six weeks. Life Sci. 2003;73(26):3339–49.CrossRefPubMedGoogle Scholar
  9. 9.
    Witkovsky P. Dopamine and retinal function. Doc Ophthalmol. 2004;108(1):17–40.CrossRefPubMedGoogle Scholar
  10. 10.
    Sakamoto K, Liu C, Kasamatsu M, Pozdeyev NV, Iuvone PM, Tosini G. Dopamine regulates melanopsin mRNA expression in intrinsically photosensitive retinal ganglion cells. Eur J Neurosci. 2005;22(12):3129–36.CrossRefPubMedGoogle Scholar
  11. 11.
    Dorenbos R, Contini M, Hirasawa H, Gustincich S, Raviola E. Expression of circadian clock genes in retinal dopaminergic cells. Vis Neurosci. 2007;24(4):573–80.CrossRefPubMedGoogle Scholar
  12. 12.
    Jackson CR, Chaurasia SS, Hwang CK, Iuvone PM. Dopamine D receptor activation controls circadian timing of the adenylyl cyclase 1/cyclic AMP signaling system in mouse retina. Eur J Neurosci. 2011;34(1):57–64.CrossRefPubMedCentralPubMedGoogle Scholar
  13. 13.
    Ruan GX, Allen GC, Yamazaki S, McMahon DG. An autonomous circadian clock in the inner mouse retina regulated by dopamine and GABA. PLoS Biol. 2008;6(10):e249.CrossRefPubMedGoogle Scholar
  14. 14.
    Weaver DR, Rivkees SA, Reppert SM. D1-dopamine receptors activate c-fos expression in the fetal suprachiasmatic nuclei. Proc Natl Acad Sci U S A. 1992;89(19):9201–4.CrossRefPubMedCentralPubMedGoogle Scholar
  15. 15.
    Ishida Y, Yokoyama C, Inatomi T, Yagita K, Dong X, Yan L, et al. Circadian rhythm of aromatic L-amino acid decarboxylase in the rat suprachiasmatic nucleus: gene expression and decarboxylating activity in clock oscillating cells. Genes Cells. 2002;7(5):447–59.CrossRefPubMedGoogle Scholar
  16. 16.
    Roybal K, Theobold D, Graham A, DiNieri JA, Russo SJ, Krishnan V, et al. Mania-like behavior induced by disruption of CLOCK. Proc Natl Acad Sci U S A. 2007;104(15):6406–11.CrossRefPubMedCentralPubMedGoogle Scholar
  17. 17.
    Castaneda TR, de Prado BM, Prieto D, Mora F. Circadian rhythms of dopamine, glutamate and GABA in the striatum and nucleus accumbens of the awake rat: modulation by light. J Pineal Res. 2004;36(3):177–85.CrossRefPubMedGoogle Scholar
  18. 18.
    Hood S, Cassidy P, Cossette MP, Weigl Y, Verwey M, Robinson B, et al. Endogenous dopamine regulates the rhythm of expression of the clock protein PER2 in the rat dorsal striatum via daily activation of D2 dopamine receptors. J Neurosci. 2010;30(42):14046–58.CrossRefPubMedGoogle Scholar
  19. 19.
    Imbesi M, Yildiz S, Dirim Arslan A, Sharma R, Manev H, Uz T. Dopamine receptor-mediated regulation of neuronal “clock” gene expression. Neuroscience. 2009;158(2):537–44.CrossRefPubMedCentralPubMedGoogle Scholar
  20. 20.
    Kafka MS, Benedito MA, Roth RH, Steele LK, Wolfe WW, Catravas GN. Circadian rhythms in catecholamine metabolites and cyclic nucleotide production. Chronobiol Int. 1986;3(2):101–15.CrossRefPubMedGoogle Scholar
  21. 21.
    McClung CA. Circadian rhythms, the mesolimbic dopaminergic circuit, and drug addiction. ScientificWorldJournal. 2007;7:194–202.CrossRefPubMedGoogle Scholar
  22. 22.
    Zisapel N. Melatonin-dopamine interactions: from basic neurochemistry to a clinical setting. Cell Mol Neurobiol. 2001;21(6):605–16.CrossRefPubMedGoogle Scholar
  23. 23.
    Eisenberg DP, Kohn PD, Baller EB, Bronstein JA, Masdeu JC, Berman KF. Seasonal effects on human striatal presynaptic dopamine synthesis. J Neurosci. 2010;30(44):14691–4.CrossRefPubMedCentralPubMedGoogle Scholar
  24. 24.
    Hampp G, Albrecht U. The circadian clock and mood-related behavior. Commun Integr Biol. 2008;1(1):1–3.CrossRefPubMedCentralPubMedGoogle Scholar
  25. 25.
    Hampp G, Ripperger JA, Houben T, Schmutz I, Blex C, Perreau-Lenz S, et al. Regulation of monoamine oxidase A by circadian-clock components implies clock influence on mood. Curr Biol. 2008;18(9):678–83.CrossRefPubMedGoogle Scholar
  26. 26.
    Bonuccelli U, Del Dotto P, Lucetti C, Petrozzi L, Bernardini S, Gambaccini G, et al. Diurnal motor variations to repeated doses of levodopa in Parkinson’s disease. Clin Neuropharmacol. 2000;23(1):28–33.CrossRefPubMedGoogle Scholar
  27. 27.
    Nutt JG, Woodward WR, Carter JH, Trotman TL. Influence of fluctuations of plasma large neutral amino acids with normal diets on the clinical response to levodopa. J Neurol Neurosurg Psychiatry. 1989;52(4):481–7.CrossRefPubMedCentralPubMedGoogle Scholar
  28. 28.
    van Hilten JJ, Kabel JF, Middelkoop HA, Kramer CG, Kerkhof GA, Roos RA. Assessment of response fluctuations in Parkinson’s disease by ambulatory wrist activity monitoring. Acta Neurol Scand. 1993;87(3):171–7.CrossRefPubMedGoogle Scholar
  29. 29.
    van Hilten JJ, Middelkoop HA, Kerkhof GA, Roos RA. A new approach in the assessment of motor activity in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1991;54(11):976–9.CrossRefPubMedCentralPubMedGoogle Scholar
  30. 30.
    Arias-Vera JR, Mansoor GA, White WB. Abnormalities in blood pressure regulation in a patient with Parkinson’s disease. Am J Hypertens. 2003;16(7):612–3.CrossRefPubMedGoogle Scholar
  31. 31.
    Devos D, Kroumova M, Bordet R, Vodougnon H, Guieu JD, Libersa C, et al. Heart rate variability and Parkinson’s disease severity. J Neural Transm. 2003;110(9):997–1011.CrossRefPubMedGoogle Scholar
  32. 32.
    Ejaz AA, Sekhon IS, Munjal S. Characteristic findings on 24-h ambulatory blood pressure monitoring in a series of patients with Parkinson’s disease. Eur J Intern Med. 2006;17(6):417–20.CrossRefPubMedGoogle Scholar
  33. 33.
    Mihci E, Kardelen F, Dora B, Balkan S. Orthostatic heart rate variability analysis in idiopathic Parkinson’s disease. Acta Neurol Scand. 2006;113(5):288–93.CrossRefPubMedGoogle Scholar
  34. 34.
    Pathak A, Senard JM. Blood pressure disorders during Parkinson’s disease: epidemiology, pathophysiology and management. Expert Rev Neurother. 2006;6(8):1173–80.CrossRefPubMedGoogle Scholar
  35. 35.
    Pursiainen V, Haapaniemi TH, Korpelainen JT, Huikuri HV, Sotaniemi KA, Myllyla VV. Circadian heart rate variability in Parkinson’s disease. J Neurol. 2002;249(11):1535–40.CrossRefPubMedGoogle Scholar
  36. 36.
    Comella CL. Sleep disorders in Parkinson’s disease: an overview. Mov Disord. 2007;22(S17):S367–73.CrossRefPubMedGoogle Scholar
  37. 37.
    Placidi F, Izzi F, Romigi A, Stanzione P, Marciani MG, Brusa L, et al. Sleep-wake cycle and effects of cabergoline monotherapy in de novo Parkinson’s disease patients. An ambulatory polysomnographic study. J Neurol. 2008;255(7):1032–7.CrossRefPubMedGoogle Scholar
  38. 38.
    Porter B, Macfarlane R, Walker R. The frequency and nature of sleep disorders in a community-based population of patients with Parkinson’s disease. Eur J Neurol. 2008;15(1):50–4.PubMedGoogle Scholar
  39. 39.
    van Hilten JJ, Weggeman M, van der Velde EA, Kerkhof GA, van Dijk JG, Roos RA. Sleep, excessive daytime sleepiness and fatigue in Parkinson’s disease. J Neural Transm. 1993;5(3):235–44.CrossRefGoogle Scholar
  40. 40.
    Verbaan D, van Rooden SM, Visser M, Marinus J, van Hilten JJ. Nighttime sleep problems and daytime sleepiness in Parkinson’s disease. Mov Disord. 2008;23(1):35–41.CrossRefPubMedGoogle Scholar
  41. 41.
    Struck LK, Rodnitzky RL, Dobson JK. Circadian fluctuations of contrast sensitivity in Parkinson’s disease. Neurology. 1990;40(3 Pt 1):467–70.CrossRefPubMedGoogle Scholar
  42. 42.
    Piccini P, Del Dotto P, Pardini C, D’Antonio P, Rossi G, Bonuccelli U. Diurnal worsening in Parkinson patients treated with levodopa. Riv Neurol. 1991;61(6):219–24.PubMedGoogle Scholar
  43. 43.
    van Hilten B, Hoff JI, Middelkoop HA, van der Velde EA, Kerkhof GA, Wauquier A, et al. Sleep disruption in Parkinson’s disease. Assessment by continuous activity monitoring. Arch Neurol. 1994;51(9):922–8.CrossRefPubMedGoogle Scholar
  44. 44.
    van Hilten JJ, Hoogland G, van der Velde EA, Middelkoop HA, Kerkhof GA, Roos RA. Diurnal effects of motor activity and fatigue in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1993;56(8):874–7.CrossRefPubMedCentralPubMedGoogle Scholar
  45. 45.
    Whitehead DL, Davies AD, Playfer JR, Turnbull CJ. Circadian rest-activity rhythm is altered in Parkinson’s disease patients with hallucinations. Mov Disord. 2008;23(8):1137–45.CrossRefPubMedGoogle Scholar
  46. 46.
    Kallio M, Haapaniemi T, Turkka J, Suominen K, Tolonen U, Sotaniemi K, et al. Heart rate variability in patients with untreated Parkinson’s disease. Eur J Neurol. 2000;7(6):667–72.CrossRefPubMedGoogle Scholar
  47. 47.
    Plaschke M, Trenkwalder P, Dahlheim H, Lechner C, Trenkwalder C. Twenty-four-hour blood pressure profile and blood pressure responses to head-up tilt tests in Parkinson’s disease and multiple system atrophy. J Hypertens. 1998;16(10):1433–41.CrossRefPubMedGoogle Scholar
  48. 48.
    Senard JM, Chamontin B, Rascol A, Montastruc JL. Ambulatory blood pressure in patients with Parkinson’s disease without and with orthostatic hypotension. Clin Auton Res. 1992;2(2):99–104.CrossRefPubMedGoogle Scholar
  49. 49.
    Haapaniemi TH, Pursiainen V, Korpelainen JT, Huikuri HV, Sotaniemi KA, Myllyla VV. Ambulatory ECG and analysis of heart rate variability in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2001;70(3):305–10.CrossRefPubMedCentralPubMedGoogle Scholar
  50. 50.
    Mastrocola C, Vanacore N, Giovani A, Locuratolo N, Vella C, Alessandri A, et al. Twenty-four-hour heart rate variability to assess autonomic function in Parkinson’s disease. Acta Neurol Scand. 1999;99(4):245–7.CrossRefPubMedGoogle Scholar
  51. 51.
    Mochizuki A, Komatsuzaki Y, Shoji S. Association of Lewy bodies and glial cytoplasmic inclusions in the brain of Parkinson’s disease. Acta Neuropathol. 2002;104(5):534–7.PubMedGoogle Scholar
  52. 52.
    Wakabayashi K, Takahashi H. Neuropathology of autonomic nervous system in Parkinson’s disease. Eur Neurol. 1997;38 Suppl 2:2–7.CrossRefPubMedGoogle Scholar
  53. 53.
    Langston J. The hypothalamus in Parkinson’s disease. Ann Neurol. 1978;3:129–33.CrossRefPubMedGoogle Scholar
  54. 54.
    Wirz-Justice A, Da Prada M, Reme C. Circadian rhythm in rat retinal dopamine. Neurosci Lett. 1984;45(1):21–5.CrossRefPubMedGoogle Scholar
  55. 55.
    Dearry A, Burnside B. Dopaminergic regulation of cone retinomotor movement in isolated teleost retinas: I. Induction of cone contraction is mediated by D2 receptors. J Neurochem. 1986;46(4):1006–21.CrossRefPubMedGoogle Scholar
  56. 56.
    Bordet R, Devos D, Brique S, Touitou Y, Guieu JD, Libersa C, et al. Study of circadian melatonin secretion pattern at different stages of Parkinson’s disease. Clin Neuropharmacol. 2003;26(2):65–72.CrossRefPubMedGoogle Scholar
  57. 57.
    Fertl E, Auff E, Doppelbauer A, Waldhauser F. Circadian secretion pattern of melatonin in de novo parkinsonian patients: evidence for phase-shifting properties of l-dopa. J Neural Transm. 1993;5(3):227–34.CrossRefGoogle Scholar
  58. 58.
    Hartmann A, Veldhuis JD, Deuschle M, Standhardt H, Heuser I. Twenty-four hour cortisol release profiles in patients with Alzheimer’s and Parkinson’s disease compared to normal controls: ultradian secretory pulsatility and diurnal variation. Neurobiol Aging. 1997;18(3):285–9.CrossRefPubMedGoogle Scholar
  59. 59.
    Pierangeli G, Provini F, Maltoni P, Barletta G, Contin M, Lugaresi E, et al. Nocturnal body core temperature falls in Parkinson’s disease but not in Multiple-System Atrophy. Mov Disord. 2001;16(2):226–32.CrossRefPubMedGoogle Scholar
  60. 60.
    Cagnacci A, Bonuccelli U, Melis GB, Soldani R, Piccini P, Napolitano A, et al. Effect of naloxone on body temperature in postmenopausal women with Parkinson’s disease. Life Sci. 1990;46(17):1241–7.CrossRefPubMedGoogle Scholar
  61. 61.
    Suzuki K, Miyamoto T, Miyamoto M, Kaji Y, Takekawa H, Hirata K. Circadian variation of core body temperature in Parkinson disease patients with depression: a potential biological marker for depression in Parkinson disease. Neuropsychobiology. 2007;56(4):172–9.CrossRefPubMedGoogle Scholar
  62. 62.
    Ben V, Blin O, Bruguerolle B. Time-dependent striatal dopamine depletion after injection of 6-hydroxydopamine in the rat. Comparison of single bilateral and double bilateral lesions. J Pharm Pharmacol. 1999;51(12):1405–8.CrossRefPubMedGoogle Scholar
  63. 63.
    Videnovic A, Noble C, Reid KJ, Peng J, Turek FW, Marconi A, et al. Circadian melatonin rhythm and excessive sleepiness in Parkinson disease. JAMA Neurol. 2014;71(4):463–9.CrossRefPubMedCentralPubMedGoogle Scholar
  64. 64.
    Breen DA, Vuono R, Nawarathna U, Fisher K, Shneerson JM, Reddy AB, et al. Sleep and circadian rhythms regulation in early Parkinson disease. JAMA Neurol. 2014;71(5):589–95.CrossRefPubMedCentralPubMedGoogle Scholar
  65. 65.
    Bolitho SJ, Naismith SL, Rajaratnam SM, Grunstein RR, Hodges JR, Terpering Z, et al. Disturbances of melatonin secretion and circadian sleep-wake regulation in Parkinson disease. Sleep Med. 2014;15(3):324–7.CrossRefGoogle Scholar
  66. 66.
    Boivin DB, James FO, Wu A, Cho-Park PF, Xiong H, Sun ZS. Circadian clock genes oscillate in human peripheral blood mononuclear cells. Blood. 2003;102(12):4143–5.CrossRefPubMedGoogle Scholar
  67. 67.
    Takimoto M, Hamada A, Tomoda A, Ohdo S, Ohmura T, Sakato H, et al. Daily expression of clock genes in whole blood cells in healthy subjects and a patient with circadian rhythm sleep disorder. Am J Physiol. 2005;289(5):R1273–9.Google Scholar
  68. 68.
    Teboul M, Barrat-Petit MA, Li XM, Claustrat B, Formento JL, Delaunay F, et al. Atypical patterns of circadian clock gene expression in human peripheral blood mononuclear cells. J Mol Med (Berl, Germany). 2005;83(9):693–9.CrossRefGoogle Scholar
  69. 69.
    Cai Y, Liu S, Sothern RB, Xu S, Chan P. Expression of clock genes Per1 and Bmal1 in total leukocytes in health and Parkinson’s disease. Eur J Neurol. 2010;17(4):550–4.Google Scholar
  70. 70.
    Shirani A, St Louis EK. Illuminating rationale and uses for light therapy. J Clin Sleep Med. 2009;5(2):155–63.PubMedCentralPubMedGoogle Scholar
  71. 71.
    Harrell LE, Balagura S. The effects of dark and light on the functional recovery following lateral hypothalamic lesions. Life Sci. 1974;15(12):2079–87.CrossRefPubMedGoogle Scholar
  72. 72.
    Willis GL, Turner EJ. Primary and secondary features of Parkinson’s disease improve with strategic exposure to bright light: a case series study. Chronobiol Int. 2007;24(3):521–37.CrossRefPubMedGoogle Scholar
  73. 73.
    Willis GL, Moore C, Armstrong SM. A historical justification for and retrospective analysis of the systematic application of light therapy in Parkinson’s disease. Rev Neurosci. 2012;23(2):199–226.PubMedGoogle Scholar
  74. 74.
    Paus S, Schmitz-Hubsch T, Wullner U, Vogel A, Klockgether T, Abele M. Bright light therapy in Parkinson’s disease: a pilot study. Mov Disord. 2007;22(10):1495–8.CrossRefPubMedGoogle Scholar
  75. 75.
    Bruinink A, Lichtensteiger W, Schlumpf M. Ontogeny of diurnal rhythms of central dopamine, serotonin and spirodecanone binding sites and of motor activity in the rat. Life Sci. 1983;33(1):31–8.CrossRefPubMedGoogle Scholar
  76. 76.
    Khaldy H, Leon J, Escames G, Bikjdaouene L, Garcia JJ, Acuna-Castroviejo D. Circadian rhythms of dopamine and dihydroxyphenyl acetic acid in the mouse striatum: effects of pinealectomy and of melatonin treatment. Neuroendocrinology. 2002;75(3):201–8.CrossRefPubMedGoogle Scholar
  77. 77.
    Weber M, Lauterburg T, Tobler I, Burgunder JM. Circadian patterns of neurotransmitter related gene expression in motor regions of the rat brain. Neurosci Lett. 2004;358(1):17–20.CrossRefPubMedGoogle Scholar
  78. 78.
    Archibald NK, Clarke MP, Mosimann UP, Burn DJ. The retina in Parkinson’s disease. Brain. 2009;132(Pt 5):1128–45.CrossRefPubMedGoogle Scholar
  79. 79.
    Matzuk MM, Saper CB. Preservation of hypothalamic dopaminergic neurons in Parkinson’s disease. Ann Neurol. 1985;18(5):552–5.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Wien 2015

Authors and Affiliations

  1. 1.Department of NeurologyNeurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical SchoolBostonUSA

Personalised recommendations